Interpace Biosciences Announces First Quarter 2022 Financial and Business Results
May 16, 2022 16:15 ET
|
Interpace Biosciences, Inc.
●Q1 Revenue of $10.4 million up 6% versus Prior Year ●Q1 Net Loss improved $2 million versus Prior Year ●Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE)...
Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results
March 31, 2022 16:15 ET
|
Interpace Biosciences, Inc.
●2021 Full Year Net Revenue of $41.3 Million up 28% vs Prior Year; Fourth Quarter Net Revenue of $10.9 Million up 13% vs Prior Year ●2021 Full Year Net Loss Improved $11.5 Million vs Prior...
Interpace Biosciences Announces Third Quarter 2021 Financial and Business Results
November 10, 2021 16:05 ET
|
Interpace Biosciences, Inc.
●Q3 Revenue of $9.5 Million is a 15% Improvement versus Q3 2020 ●Year to Date Revenue of $30.5 Million Up 34% Versus Prior Year ●Second Consecutive Record Cash Collection Quarter ●Significantly...
Interpace Biosciences Announces New $8 Million Term Loan with BroadOak Capital Partners and Repayment of Private Equity Loans
November 02, 2021 16:15 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that it, along with its subsidiaries, has entered into a...
Interpace Biosciences Announces Second Quarter 2021 Financial and Business Results
August 10, 2021 16:05 ET
|
Interpace Biosciences, Inc.
●Q2 Revenue of $11.2 Million Surpasses Q1 2021 as Company’s Highest Revenue Quarter ●Company approaching EBITDA breakeven on Higher Clinical Volume, Revenue, Improved Gross Profit and Operating...
Interpace Pharma Solutions Announces New Advanced Offering in RNA Biomarker Analysis
April 12, 2021 07:05 ET
|
Interpace Biosciences, Inc.
Parsippany, NJ, April 12, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today new capability...
Interpace Biosciences Announces Path Forward in Letter to Shareholders
February 16, 2021 21:21 ET
|
Interpace Biosciences, Inc.
PARSIPPANY, NJ, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) (“Interpace”), a leader in enabling personalized medicine, issued the following communication to...
Interpace Biosciences Announces Executive Transition: Jack Stover to Retire as President and Chief Executive Officer Thomas Burnell Appointed as Successor
November 25, 2020 08:12 ET
|
Interpace Biosciences, Inc.
Parsippany, NJ, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) today announced that Jack Stover, President & Chief Executive Officer, will retire effective December...